Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™.

Vaccine - 24 Apr 2023

Xu Senyu, Duan Huixin, An Yaling, Jin Xiyue, Duan Minrun, Dubois Patrice M, Huang Yan, Xu Kun, Du Heng, Kleanthous Harry, Dai Lianpan, Gao George F

Abstract excerpt

Protein subunit vaccines have been widely used to combat infectious diseases, including the current COVID-19 pandemic. Adjuvants play the key role in shaping the quality and magnitude of the immune response to protein and inactivated vaccines. We previously developed a protein subunit COVID-19 vaccine, termed ZF2001, based on an aluminium hydroxide-adjuvanted tandem-repeat dimeric receptor-binding domain (RBD) of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Viral
Share to Binding Sites

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line

Share to COVID-19 Vaccines

Share to Mice, Inbred BALB C

Share to Protein Multimerization

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 36967286
DOI: 10.1016/j.vaccine.2023.03.035
PMCID: PMC10028357

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™.PMID 36967286Read ↗

Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD)Semantic proximity Read ↗

Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernSemantic proximity Read ↗

Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19Semantic proximity Read ↗

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity Read ↗

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike AntigensSemantic proximity Read ↗

Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigensSemantic proximity Read ↗

Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunitySemantic proximity Read ↗

Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine - BBV152Semantic proximity Read ↗

Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 TrialSemantic proximity Read ↗

An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmissionSemantic proximity Read ↗

Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell linesSemantic proximity Read ↗

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.